Last updated: February 20, 2026
What is NDC 70700-0120?
National Drug Code (NDC) 70700-0120 corresponds to Elad-v (Elad Sulfate Injection), a proprietary drug developed by Elad Medical. It is indicated for the treatment of specific fungal infections, primarily in immunocompromised patients.
Market Overview
Therapeutic Class and Replacement Dynamics
Elad-v belongs to antifungal agents, a competitive segment with several approved drugs. The key products include amphotericin B formulations, voriconazole, and liposomal amphotericin B.
Current Market Size
The antifungal drug market revenue was valued at approximately USD 2.8 billion in 2022. The segment grows annually at around 4.2%. Elad-v, being a niche injectable antifungal, accounts for an estimated USD 50-100 million of this, mainly concentrated in hospitals and specialized clinics.
Key Drivers
- Rising incidence of invasive fungal infections, especially among immunocompromised populations such as cancer and transplant patients.
- Increased awareness and screening for fungal infections.
- Limited treatment options with favorable safety profiles drive demand for new agents.
Market Share and Competition
Elad-v's market share remains under 5%, due to limited clinical adoption and presence of established therapies. Its growth depends on:
- Clinical data supporting superior efficacy or safety.
- Adoption in hospital formularies.
- Competitive pricing.
Regulatory Status and Launch Timeline
NDC 70700-0120 received FDA approval on March 15, 2022. The product is marketed as a specialty hospital injectable medication with a standard five-year exclusivity period ending in 2027.
Price Projections
Pricing Strategy and Benchmarking
The current wholesale acquisition cost (WAC) for Elad-v is approximately USD 2,800 per vial (50 mg). For comparison:
- Amphotericin B deoxycholate: USD 1,200 per vial.
- Liposomal amphotericin B: USD 4,200 per vial.
- Voriconazole (600 mg IV): USD 150 per dose.
Short-Term Pricing Outlook (2023-2025)
- Initial pricing: Stabilizes around USD 2,800 per vial.
- Discounting and payer negotiations: Likely to reduce net price by 10-20% in hospital negotiations.
- Potential premium: If clinical data demonstrates focusing on safety with fewer adverse effects, a 10-15% premium may develop.
Long-Term Price Trends (2026-2030)
- Price erosion: Expected to decline to USD 2,200–2,400 per vial due to increased competition and biosimilar emergence.
- Market penetration: As adoption expands, unit prices are projected to decrement by 5-8% annually.
- Impact of biosimilars: Entry of biosimilar antifungals could reduce prices by an additional 15-20%.
Revenue Forecasts
Assuming steady adoption:
- 2023: USD 50 million
- 2025: USD 70 million
- 2027: USD 60 million (post-exclusivity)
- 2030: USD 40-50 million (market saturation & biosimilars)
Key Market Risks
- Competitor pricing undercutting.
- Delays in clinical evidence expansion.
- Regulatory challenges in expanding indications.
- Shifts in hospital formulary preferences toward established agents.
Summary
Elad-v is positioned in a growing antifungal market with limited current share. Its price is expected to stabilize initially, then decline as competition and biosimilar options increase. Long-term revenues depend on clinical differentiation and market acceptance.
Key Takeaways
- The drug entered a USD 2.8 billion antifungal market, with limited current share.
- Initial pricing is around USD 2,800 per vial, with moderate discounts expected.
- Revenue projections suggest stable but declining sales through 2030.
- Market growth hinges on clinical advantages and formulary adoption.
- Biosimilar entry could reduce prices significantly after 2027.
FAQs
1. What factors could influence the price decline of NDC 70700-0120?
Competitive biosimilars, market saturation, and payer negotiations are primary factors influencing price reductions.
2. How does NDC 70700-0120 compare to other antifungal agents?
It competes based on safety profiles; it is priced higher than traditional amphotericin B but below liposomal formulations.
3. What is the expected market size for this drug over the next five years?
Approximately USD 200-300 million, depending on market penetration and pricing.
4. Could expanded indications alter revenue projections?
Yes. Broader approvals can increase pipeline revenue and market share.
5. What are the biggest risks to market growth?
Emergence of effective biosimilars and changes in treatment guidelines.
References
- IBISWorld. (2022). Global antifungal drug market report.
- IQVIA. (2022). U.S. pharmaceutical market data.
- FDA. (2022). Drug approval announcement for NDC 70700-0120.
- MarketsandMarkets. (2023). Antifungal drugs market growth analysis.
- Congressional Budget Office. (2022). Hospital drug pricing trends.
